Allergan launches Saphris 2.5 mg sublingual tablets in US
In March this year, the company secured approval from the US Food and Drug Administration (FDA) for Saphris for the acute treatment of manic or mixed episodes associated
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
About 360 patients with DES will be included in the multicenter, randomized, double-masked Phase IIb/III trial, which will evaluate the efficacy and superiority of GBT-201 compared to placebo.
C2N-8E12 is a humanized antibody that targets the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer’s disease (AD).